mRNA-loaded apolipoprotein A1 nanoparticles

mRNA-loaded apolipoprotein A1 nanoparticles (aNPs) are a nature-inspired delivery platform designed to transport messenger RNA (mRNA) to immune cells within secondary lymphoid organs, such as the spleen and lymph nodes. Developed by Biotrip in collaboration with the Eindhoven University of Technology and Radboud University Medical Center, these nanoparticles utilize a combination of apolipoprotein A1 and proprietary dendrimer-based ionizable lipids (e.g., HMJ1, HMJ2) to encapsulate mRNA. The primary therapeutic strategy involves delivering mRNA encoding cytokines, such as human interleukin-2 (hIL-2) or interferon-gamma (IFN-gamma), to stimulate local immune responses and activate CD8+ T cells for cancer immunotherapy. This approach aims to achieve robust immunomodulation while minimizing the systemic toxicity often associated with traditional cytokine treatments. Preclinical studies in mouse models of melanoma and colorectal cancer have demonstrated significant tumor growth inhibition and improved survival, with additional validation performed in non-human primates and patient-derived monocytes.

Other names

apolipoprotein A1 nanoparticlesaNP platform